Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Lenora Davis"'
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e98515 (2014)
Aberrant kinase activation resulting from mutation, amplification, or translocation can drive growth and survival in a subset of human cancer. FGFR2 is amplified in breast and gastric cancer, and we report here the first characterization of FGFR2 gen
Externí odkaz:
https://doaj.org/article/cfd719341154414c995aba7fe686a68d
Autor:
Bart Lutterbach, Cem Elbi, Alessandra Di Bacco, Masakazu Yashiro, Harold Hatch, Julie Gorenstein, Lenora Davis, Kaiko Kunii
We have identified a critical role for amplified FGFR2 in gastric cancer cell proliferation and survival. In a panel of gastric cancer cell lines, fibroblast growth factor receptor 2 (FGFR2) was overexpressed and tyrosine phosphorylated selectively i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47db3f833a134adf73f50cc43e6171a7
https://doi.org/10.1158/0008-5472.c.6497708
https://doi.org/10.1158/0008-5472.c.6497708
Autor:
Bart Lutterbach, Cem Elbi, Alessandra Di Bacco, Masakazu Yashiro, Harold Hatch, Julie Gorenstein, Lenora Davis, Kaiko Kunii
Supplementary Figures 1-10 from FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41777d8fd16e16d9fdbcb66fa62325dd
https://doi.org/10.1158/0008-5472.22375091
https://doi.org/10.1158/0008-5472.22375091
Autor:
Jason D. Katz, Bart Lutterbach, Harold Hatch, Robert J. Mathvink, Wenxian Wang, Xianlu Qu, Kaiko Kunii, C. Gary Marshall, Bo-Sheng Pan, Keith W. Rickert, Craig Rosenstein, Alexander A. Szewczak, Jonathan R. Young, Kevin J. Lumb, David Joseph Guerin, Sangita B. Patel, Gaozhen Hang, Qinwen Zeng, Sujal V. Deshmukh, Deborah Walker, Danielle Falcone, Stephen M. Soisson, Lenora Davis, Rachael Holmes, Kerrie Spencer, William K. Dahlberg, Wei Lu, James P. Jewell, Ana Esther Ortega Gabarda, Naim Nazef, Michael D. Altman, Christopher J. Dinsmore, John F. Reilly, Jongwon Lim
Publikováno v:
Journal of Medicinal Chemistry. 54:4092-4108
c-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes. In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering
Autor:
Lenora Davis, Alessandra Di Bacco, Harold Hatch, Kaiko Kunii, Bart Lutterbach, Cem Elbi, Masakazu Yashiro, Julie Gorenstein
Publikováno v:
Cancer Research. 68:2340-2348
We have identified a critical role for amplified FGFR2 in gastric cancer cell proliferation and survival. In a panel of gastric cancer cell lines, fibroblast growth factor receptor 2 (FGFR2) was overexpressed and tyrosine phosphorylated selectively i
Autor:
Xianzhi Mao, Elaine Rands, Laura Sepp-Lorenzino, Patrice A. Ciecko, Susan Hill, Jennifer M. Shipman, William F. Hoffman, Brett Connolly, Mark E. Fraley, Stephen C. Beck, Kathleen E. Coll, Kenneth A. Thomas, David C. Heimbrook, Keith W. Rickert, Lenora Davis, Jackson B. Gibbs, Nancy E. Kohl, Joanne Antanavage, George D. Hartman
Publikováno v:
Cancer Research. 64:751-756
A strategy for antagonizing vascular endothelial growth factor (VEGF) -induced angiogenesis is to inhibit the kinase activity of its receptor, kinase insert domain-containing receptor (KDR), the first committed and perhaps the last unique step in the
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e98515 (2014)
PLoS ONE
PLoS ONE
Aberrant kinase activation resulting from mutation, amplification, or translocation can drive growth and survival in a subset of human cancer. FGFR2 is amplified in breast and gastric cancer, and we report here the first characterization of FGFR2 gen
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1310:119-126
N1-guanyl-1,7-diaminoheptane (GC7) is a potent inhibitor of deoxyhypusine synthase (DHS), the enzyme that catalyzes the first step in the hypusination of eukaryotic translation initiation factor 5A (eIF-5A). Since eIF-5A is the only known cellular su
Autor:
Massimo Loda, Elisa Benedettini, Bo Sheng Pan, Victoria M. Richon, Michelangelo Fiorentino, John F. Reilly, Dyane Bailey, Lenora Davis, Lucian R. Chirieac, John D. Minna, Natalie Vena, Silvano Bosari, Christopher Ware, Bart Lutterbach, Azra H. Ligon, Adi F. Gazdar, Michael Peyton, Giulio Draetta, Beow Y. Yeap, Lynette M. Sholl
Most non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitor (TKI) therapy. However, about 30% exhibit primary resistance to EGFR TKI therapy. Here we rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c56e62ac6232b5f60d5a3c1bf3469316
http://hdl.handle.net/11585/577838
http://hdl.handle.net/11585/577838
Autor:
Edward M. Scolnick, Scott D. Mosser, R D Keys, Lenora Davis, Jackson B. Gibbs, Mark S. Marshall, W. S. Hill
Publikováno v:
Molecular and Cellular Biology. 11:3997-4004
The Krev-1 gene has been shown to suppress ras-mediated transformation in vitro. Both ras and Krev-1 proteins have identical effector domains (ras residues 32 to 40), which are required for biological activity and for the interaction of Ras p21 with